Literature DB >> 26686391

Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135.

Maria Antonietta De Luca1, M Paola Castelli2, Barbara Loi3, Alessandra Porcu2, Mariella Martorelli2, Cristina Miliano2, Kathryn Kellett3, Colin Davidson4, Jacqueline L Stair3, Fabrizio Schifano3, Gaetano Di Chiara5.   

Abstract

In order to investigate the in vivo dopamine (DA) stimulant properties of selected 3rd generation Spice/K2 cannabinoids, BB-22, 5F-PB-22, 5F-AKB-48 and STS-135, their in vitro affinity and agonist potency at native rat and mice CB1 receptors was studied. The compounds bind with high affinity to CB1 receptors in rat cerebral cortex homogenates and stimulate CB1-induced [(35)S]GTPγS binding with high potency and efficacy. BB-22 and 5F-PB-22 showed the lowest Ki of binding to CB1 receptors (0.11 and 0.13 nM), i.e., 30 and 26 times lower respectively than that of JWH-018 (3.38 nM), and a potency (EC50, 2.9 and 3.7 nM, respectively) and efficacy (Emax, 217% and 203%, respectively) as CB1 agonists higher than JWH-018 (EC50, 20.2 nM; Emax, 163%). 5F-AKB-48 and STS-135 had higher Ki for CB1 binding, higher EC50 and lower Emax as CB1 agonists than BB-22 and 5F-PB-22 but still comparatively more favourable than JWH-018. The agonist properties of all the compounds were abolished or drastically reduced by the CB1 antagonist/inverse agonist AM251 (0.1 μM). No activation of G-protein was observed in CB1-KO mice. BB-22 (0.003-0.01 mg/kg i.v.) increased dialysate DA in the accumbens shell but not in the core or in the medial prefrontal cortex, with a bell shaped dose-response curve and an effect at 0.01 mg/kg and a biphasic time-course. Systemic AM251 (1.0 mg/kg i.p.) completely prevented the stimulant effect of BB-22 on dialysate DA in the NAc shell. All the other compounds increased dialysate DA in the NAc shell at doses consistent with their in vitro affinity for CB1 receptors (5F-PB-22, 0.01 mg/kg; 5F-AKB-48, 0.1 mg/kg; STS-135, 0.15 mg/kg i.v.). 3rd generation cannabinoids can be even more potent and super-high CB1 receptor agonists compared to JWH-018. Future research will try to establish if these properties can explain the high toxicity and lethality associated with these compounds.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CB1 receptors; Cannabinoids; Dopamine; GTPγS binding; K2; Microdialysis; Spice

Mesh:

Substances:

Year:  2015        PMID: 26686391     DOI: 10.1016/j.neuropharm.2015.11.017

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  20 in total

1.  In vitro determination of the efficacy of illicit synthetic cannabinoids at CB1 receptors.

Authors:  Shivani Sachdev; Kiran Vemuri; Samuel D Banister; Mitchell Longworth; Michael Kassiou; Marina Santiago; Alexandros Makriyannis; Mark Connor
Journal:  Br J Pharmacol       Date:  2019-12-10       Impact factor: 8.739

Review 2.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

3.  Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of five novel synthetic cannabinoids in rats.

Authors:  Michael B Gatch; Michael J Forster
Journal:  Psychopharmacology (Berl)       Date:  2017-11-14       Impact factor: 4.530

Review 4.  How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe.

Authors:  Raquel Santos-Toscano; Amira Guirguis; Colin Davidson
Journal:  Br J Clin Pharmacol       Date:  2020-02-23       Impact factor: 4.335

Review 5.  New vistas on cannabis use disorder.

Authors:  Miriam Melis; Roberto Frau; Peter W Kalivas; Sade Spencer; Vivian Chioma; Erica Zamberletti; Tiziana Rubino; Daniela Parolaro
Journal:  Neuropharmacology       Date:  2017-03-31       Impact factor: 5.250

6.  Structure-activity relationships for 5F-MDMB-PICA and its 5F-pentylindole analogs to induce cannabinoid-like effects in mice.

Authors:  Grant C Glatfelter; John S Partilla; Michael H Baumann
Journal:  Neuropsychopharmacology       Date:  2021-11-20       Impact factor: 8.294

7.  Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies.

Authors:  Isabella Canazza; Andrea Ossato; Claudio Trapella; Anna Fantinati; Maria Antonietta De Luca; Giulia Margiani; Fabrizio Vincenzi; Claudia Rimondo; Fabiana Di Rosa; Adolfo Gregori; Katia Varani; Pier Andrea Borea; Giovanni Serpelloni; Matteo Marti
Journal:  Psychopharmacology (Berl)       Date:  2016-08-15       Impact factor: 4.530

Review 8.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

9.  Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation.

Authors:  Rachelle Abouchedid; James H Ho; Simon Hudson; Alison Dines; John R H Archer; David M Wood; Paul I Dargan
Journal:  J Med Toxicol       Date:  2016-07-25

10.  Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity.

Authors:  Anna Pinson; Azure L Yarbrough; John M Bush; Christian V Cabanlong; Amal Shoeib; Bailey K Jackson; Saki Fukuda; Jyoti Gogoi; William E Fantegrossi; Keith McCain; Paul L Prather; Ryoichi Fujiwara; Anna Radominska-Pandya
Journal:  Pharmacol Biochem Behav       Date:  2020-05-13       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.